423 related articles for article (PubMed ID: 9170522)
1. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
3. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
5. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
[TBL] [Abstract][Full Text] [Related]
7. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
[TBL] [Abstract][Full Text] [Related]
9. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
Miyoshi Y; Matsuzaki J; Miura T
Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
[TBL] [Abstract][Full Text] [Related]
12. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
13. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
14. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD
BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
17. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
18. Screening and monitoring for bladder cancer: refining the use of NMP22.
Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD
J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
Kurokawa S; Morita T; Muraishi O; Tokue A
Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
